Collaboration with Quadram Institute Bioscience Will Focus on New Therapies for Immune-Related Conditions
DuPont Nutrition and Biosciences announced a 3-year project to study gut bacteria’s influence the immune system. The company is partnering with Quadram Institute Bioscience (QIB) to complete the focus.
The research will evaluate how extracellular vesicles (EVs), which are naturally produced by the gut bacteria, can be used to enhance immunity and prevent or treat inflammatory conditions. A key step to having a better understanding of the human health and diseases is to understand the interaction between gut bacteria and the body as such scientific findings are increasingly used to develop new strategies for the treatment and prevention of health conditions.
Sebastien Guery, leader of DuPont’s Human Microbiome Venture said, “We are delighted to be partnering with Quadram Institute Bioscience, a world leader in the science and technology of extracellular vesicles produced by gut bacteria. If successful, the project will provide the basis for a new form of immunotherapy based on gut bacterial extracellular vesicles that will be taken forward for human clinical trials. I believe this technology has the potential to reduce the global burden of infectious and chronic diseases.”
This is DuPont’s fifth research collaboration since the establishment of the DuPont Microbiome Venture in late 2017.